… Arribas and colleagues [68] found that patients with ventriculoencephalitis, radiculomyelitis,
… Arribas and colleagues cautioned that the implication of low levels of cytomegalovirus DNA …

… Dr Jose R Arribas, MD Jose R Arribas … Correspondence to: Dr Jose R Arribas, Infectious
Diseases Unit, Department of Internal Medicine, La Paz-Carlos III University Hospital, IdiPAZ, …

Background To date, no immunological data on COVID-19 heterologous vaccination schedules
in humans have been reported. We assessed the immunogenicity and reactogenicity of …

Background The prevalence of SARS-CoV-2 infection among health care workers (HCWs)
provides information about the spread of COVID-19 within health care facilities, and the risk …

Background Durable suppression of replication of the human immunodeficiency virus (HIV)
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …

Background: Since the confirmation of the first patient infected with SARS-CoV-2 in Spain in
January 2020, the epidemic has grown rapidly, with the greatest impact on the region of …

… Arribas received consulting fees from Abbott Laboratories, Bristol-Myers Squibb, Gilead
Sciences, GlaxoSmithKline, Tibotec, and Roche. A. Pozniak received consulting fees, …

Background Our objective was to assess therapeutic non-inferiority of dual treatment with
lopinavir–ritonavir and lamivudine to triple treatment with lopinavir–ritonavir plus two nucleos(t)…

Objectives To analyse the characteristics and predictors of death in hospitalized patients
with coronavirus disease 2019 (COVID-19) in Spain. Methods A retrospective observational …

Background Molnupiravir is an oral prodrug of β-D-N4-hydroxycytidine, active against SARS-CoV-2
in vitro and in animal models. We report data from the phase 2 component of MOVe-…